These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 33031827)
41. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994 [TBL] [Abstract][Full Text] [Related]
42. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma. Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814 [TBL] [Abstract][Full Text] [Related]
43. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy]. Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966 [No Abstract] [Full Text] [Related]
44. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
45. Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p/IL6R axis for the activation of JAK2/STAT3 pathway. Li JL; Liu XL; Guo SF; Yang Y; Zhu YL; Li JZ Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9238-9250. PubMed ID: 31773675 [TBL] [Abstract][Full Text] [Related]
46. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib. Łuczkowska K; Kulig P; Baumert B; Machaliński B Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501221 [TBL] [Abstract][Full Text] [Related]
47. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ]. Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899 [TBL] [Abstract][Full Text] [Related]
48. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103 [TBL] [Abstract][Full Text] [Related]
49. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone. Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782 [TBL] [Abstract][Full Text] [Related]
50. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554 [No Abstract] [Full Text] [Related]
51. CircITCH: A Circular RNA With Eminent Roles in the Carcinogenesis. Ghafouri-Fard S; Khoshbakht T; Taheri M; Jamali E Front Oncol; 2021; 11():774979. PubMed ID: 34722322 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577 [TBL] [Abstract][Full Text] [Related]
53. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway]. Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252 [TBL] [Abstract][Full Text] [Related]
54. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms]. Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400 [No Abstract] [Full Text] [Related]
55. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Kim A; Seong KM; Kang HJ; Park S; Lee SS Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678 [TBL] [Abstract][Full Text] [Related]
56. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation. Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004 [TBL] [Abstract][Full Text] [Related]
57. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression. Wang X; Li H; Shi J Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988 [TBL] [Abstract][Full Text] [Related]
58. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707 [TBL] [Abstract][Full Text] [Related]
59. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124 [TBL] [Abstract][Full Text] [Related]
60. Inhibition of sepsis-induced acute kidney injury via the circITCH-miR-579-3p-ZEB2 axis. Li Q; Wang T; Wang X; Ge XY; Yang T; Bai G; Wang W Environ Toxicol; 2023 Jun; 38(6):1217-1225. PubMed ID: 36999488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]